Trial Profile
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results assessing vascular response using DCE-MRI to predict the efficacy of axitinib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.
- 20 Jul 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2016.